ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

hafnium oxide

Also written as “JNJ-90301900”, “PEP503” and “JNJ-90301900 (NBTXR3)”.

Its studies are mostly in Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small-Cell Lung · Rectal Neoplasms, led by 3 companies.

Drug pageHafnium oxide: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 4, 20216 company-led studies, 4 open or runningNext primary completion: Apr 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only33 open or runningphase 3since May 4, 2021May 4, 2021Jun 30, 2028phase 3 · NCT04892173
PharmaEngineits history only20 open or runningphase 2since Jun 1, 2015Jun 1, 2015none ahead
Nanobiotix11 open or runningphase 1since Apr 10, 2018Apr 10, 2018Apr 30, 2027phase 1 · NCT03589339
  • Named in Johnson & Johnson’s own pipeline as JNJ-1900 (NBTXR3), phase 3, as of Oct 13, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Nanobiotix only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 10, 2018First study: phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT03589339 · 145 enrolled · United States

Ahead

  1. Apr 30, 2027Primary completion: phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT03589339

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Nanobiotix leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03589339Squamous Cell Carcinoma of Head and Neck · United States1Active, not recruitingApr 30, 2027145

How it is read

Names in the registry

  • “JNJ-90301900”, 2 entries
  • “PEP503”, 2 entries
  • “JNJ-90301900 (NBTXR3)”, 1 entry
  • “NBTXR3”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.